NCT02619760CompletedPhase 4
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
Source: ClinicalTrials.gov · Last updated 14 Jun 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 3045 (actual)
- First submitted
- 29 Nov 2015
- Start date
- Dec 2015
- Primary completion date
- 8 Dec 2018
- Lead sponsor
- Kyoto University, Graduate School of Medicine
- Diseases
- Coronary artery disease
- NCT number
- NCT02619760
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 3045
- From Dec 2015 to the primary completion date, 8 Dec 2018
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents (Xience) implanted at the time of enrollment
- Patients requiring continuous administration of antiplaelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment
- Patients with coronary bioabsorbable vascular scaffolds (BVS) implanted prior to or at the time of enrollment
Other illness
- Patients with medical history of intracranial hemorrhage
- Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention
Other
- Patients requiring oral anticoagulants
- Patients comfirmed to have no tolerability to clopidgorel before enrollment
Who the study is looking for
- Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent
- Patients who are capable of oral dual antiplatelet therapy consisting of asprin and P2Y12 receptor antagonist
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Division of Cardiology, Kyoto University Hospital Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
Related publications
- Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort.Circ Cardiovasc Interv · 2026 · PMID 41847750
This page is information, not medical advice. Discuss any trial with your doctor.